- Home
- ACAD vs NSIT Comparison
ACAD vs NSIT Comparison
Compare ACAD & NSIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- NSIT
- Stock Information
- Founded
- ACAD 1993
- NSIT 1988
- Country
- ACAD United States
- NSIT United States
- Employees
- ACAD N/A
- NSIT N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- NSIT EDP Services
- Sector
- ACAD Health Care
- NSIT Technology
- Exchange
- ACAD Nasdaq
- NSIT Nasdaq
- Market Cap
- ACAD 3.8B
- NSIT 4.3B
- IPO Year
- ACAD 2004
- NSIT 1995
- Fundamental
- Price
- ACAD $20.98
- NSIT $139.99
- Analyst Decision
- ACAD Buy
- NSIT Buy
- Analyst Count
- ACAD 18
- NSIT 4
- Target Price
- ACAD $27.71
- NSIT $185.00
- AVG Volume (30 Days)
- ACAD 2.1M
- NSIT 297.3K
- Earning Date
- ACAD 08-05-2025
- NSIT 07-31-2025
- Dividend Yield
- ACAD N/A
- NSIT N/A
- EPS Growth
- ACAD N/A
- NSIT N/A
- EPS
- ACAD 1.37
- NSIT 5.12
- Revenue
- ACAD $996,283,000.00
- NSIT $8,425,769,000.00
- Revenue This Year
- ACAD $13.39
- NSIT $3.19
- Revenue Next Year
- ACAD $10.59
- NSIT $4.72
- P/E Ratio
- ACAD $15.33
- NSIT $27.33
- Revenue Growth
- ACAD 22.42
- NSIT N/A
- 52 Week Low
- ACAD $13.40
- NSIT $126.10
- 52 Week High
- ACAD $25.23
- NSIT $228.07
- Technical
- Relative Strength Index (RSI)
- ACAD 45.70
- NSIT 53.26
- Support Level
- ACAD $20.75
- NSIT $140.71
- Resistance Level
- ACAD $23.09
- NSIT $146.83
- Average True Range (ATR)
- ACAD 0.78
- NSIT 3.63
- MACD
- ACAD -0.20
- NSIT 0.59
- Stochastic Oscillator
- ACAD 9.83
- NSIT 56.82
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About NSIT Insight Enterprises Inc.
Insight Enterprises Inc is a Fortune IT provider engaged in helping businesses of all sizes, large enterprises, governments, schools, and healthcare organizations. The company has three geographic operating segments: North America, EMEA, and APAC. It generates maximum revenue from the North America segment. The company provides digital innovation, cloud/data center transformation, connected workforce, and supply chain optimization solutions and services.